Treatment sequencing in resectable lung cancer: the good and the bad of adjuvant versus neoadjuvant therapy
The treatment scenario for patients with resectable non–small cell lung cancer has changed
dramatically with the incorporation of immunotherapy. The introduction of immunotherapy …
dramatically with the incorporation of immunotherapy. The introduction of immunotherapy …
Pre-analytical conditions and implementation of quality control steps in liquid biopsy analysis
A Ntzifa, E Lianidou - Critical Reviews in Clinical Laboratory …, 2023 - Taylor & Francis
Over the last decade, great advancements have been made in the field of liquid biopsy
through extensive research and the development of new technologies that facilitate the use …
through extensive research and the development of new technologies that facilitate the use …
Detecting ALK, ROS1, and RET fusions and the METΔex14 splicing variant in liquid biopsies of non‐small‐cell lung cancer patients using RNA‐based techniques
A Giménez‐Capitán, E Sánchez‐Herrero… - Molecular …, 2023 - Wiley Online Library
ALK, ROS1, and RET fusions and MET∆ ex14 variant associate with response to targeted
therapies in non‐small‐cell lung cancer (NSCLC). Technologies for fusion testing in tissue …
therapies in non‐small‐cell lung cancer (NSCLC). Technologies for fusion testing in tissue …
[HTML][HTML] Analysis of circulating tumour DNA to identify patients with epidermal growth factor receptor–positive non-small cell lung cancer who might benefit from …
M Provencio, R Serna-Blasco, F Franco, V Calvo… - European Journal of …, 2021 - Elsevier
Background Survival data support the use of first-line osimertinib as the standard of care for
epidermal growth factor receptor (EGFR)–positive non-small cell lung cancer (NSCLC) …
epidermal growth factor receptor (EGFR)–positive non-small cell lung cancer (NSCLC) …
Comparison between three different techniques for the detection of EGFR mutations in liquid biopsies of patients with advanced stage lung adenocarcinoma
Oncogenic mutations in the EGFR gene are targets of tyrosine kinase inhibitors (TKIs) in
lung adenocarcinoma (LC) patients, and their search is mandatory to make decisions on …
lung adenocarcinoma (LC) patients, and their search is mandatory to make decisions on …
Circulating tumor DNA as a cancer biomarker: an overview of biological features and factors that may impact on ctDNA analysis
E Sánchez-Herrero, R Serna-Blasco… - Frontiers in …, 2022 - frontiersin.org
Cancer cells release nucleic acids, freely or associated with other structures such as
vesicles into body fluids, including blood. Among these nucleic acids, circulating tumor DNA …
vesicles into body fluids, including blood. Among these nucleic acids, circulating tumor DNA …
Liquid biopsy: early and accurate diagnosis of brain tumor
Z Yi, C Qu, Y Zeng, Z Liu - Journal of Cancer Research and Clinical …, 2022 - Springer
Noninvasive examination is an emerging area in the field of neuro-oncology. Liquid biopsy
captures the landscape of genomic alterations of brain tumors and revolutionizes the …
captures the landscape of genomic alterations of brain tumors and revolutionizes the …
Use of liquid biopsy in the care of patients with non-small cell lung cancer
A Romero, R Serna-Blasco, V Calvo… - … Treatment Options in …, 2021 - Springer
Opinion Statement Recent technological advances have enabled the development of liquid
biopsy-based approaches, which have revolutionized the diagnostic world. The analysis of …
biopsy-based approaches, which have revolutionized the diagnostic world. The analysis of …
Detection of EGFR mutations from plasma of NSCLC patients using an automatic cartridge-based PCR system
S Heeke, V Hofman, J Benzaquen, J Otto… - Frontiers in …, 2021 - frontiersin.org
The introduction of liquid biopsies for the detection of EGFR mutations in non-small cell lung
cancer patients (NSCLC) has revolutionized the clinical care. However, liquid biopsies are …
cancer patients (NSCLC) has revolutionized the clinical care. However, liquid biopsies are …
ALK-Fusion Transcripts Can Be Detected in Extracellular Vesicles (EVs) from Nonsmall Cell Lung Cancer Cell Lines and Patient Plasma: Toward EV-Based …
E Sánchez-Herrero, C Campos-Silva… - Clinical …, 2022 - academic.oup.com
Background ALK rearrangements are present in 5% of nonsmall cell lung cancer (NSCLC)
tumors and identify patients who can benefit from ALK inhibitors. ALK fusions testing using …
tumors and identify patients who can benefit from ALK inhibitors. ALK fusions testing using …